Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma

BACKGROUND: The utility of O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status as a prognostic marker in patients with glioblastoma (GBM) has been established. However, the number of CpG sites that must be methylated to cause transcriptional silencing remains unclear, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanihara, Mitsuto, Miyake, Kunio, Watanabe, Atsushi, Yamada, Yuriko, Oishi, Naoki, Kawataki, Tomoyuki, Inukai, Takeshi, Kondo, Tetsuo, Kinouchi, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672949/
https://www.ncbi.nlm.nih.gov/pubmed/33203454
http://dx.doi.org/10.1186/s13148-020-00968-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672949/
https://www.ncbi.nlm.nih.gov/pubmed/33203454
http://dx.doi.org/10.1186/s13148-020-00968-5

Ejemplares similares